Valda datamodeller

Du måste vara inloggad för att välja flera datamodeller, ladda ner dem eller analysera dem.

48 Sökresultat.
Relevans Bedömning Nya först Gamla först

Eligibility Kidney Cancer NCT00365768

- 2016-10-03 - 1 Formulär, 2 Item-grupper, 9 Dataelement, 1 Språk
Item-grupper: Inclusion Criteria, Exclusion Criteria
Glutamine in Treating Neuropathy Caused by Vincristine in Young Patients With Lymphoma, Leukemia, or Solid Tumors; ODM derived from: https://clinicaltrials.gov/show/NCT00365768

Treatment Form Kidney Cancer (NCT01198158)

- 2015-01-08 - 1 Formulär, 6 Item-grupper, 39 Dataelement, 1 Språk
Item-grupper: Header Module, Patient Information, Urinalysis Day 1, Urinalysis Day 15, Everolimus, Bevacizumab/Placebo Information
CALGB 90802 Treatment Form Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy NCT01198158 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=87963E33-F0BE-4A17-E040-BB89AD433B67

Follow-Up Form Kidney Cancer (NCT01198158)

- 2015-01-09 - 1 Formulär, 8 Item-grupper, 57 Dataelement, 1 Språk
Item-grupper: Header Module, Vital Status, Disease Assessment, Measurable Disease Response, LABORATORY DATA, Notice of New Primary, Long-Term Toxicity, Non-Protocol Therapy
CALGB 90802 Follow-Up Form Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy NCT01198158 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=87856A36-E884-CA3E-E040-BB89AD431C27

Off-Treatment Form Kidney Cancer (NCT00326898)

- 2015-01-07 - 1 Formulär, 3 Item-grupper, 24 Dataelement, 1 Språk
Item-grupper: Header, Vital Status, Treatment
E2805 Off-Treatment Form Sunitinib or Sorafenib in Treating Patients With Kidney Cancer That Was Removed By Surgery NCT00326898 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=054AD4FB-BA76-2822-E044-0003BA3F9857

Eligibility NCT00655252 Metastatic Renal Cell Cancer - Eligibility

- 2013-12-09 - 1 Formulär, 2 Item-grupper, 10 Dataelement, 2 Språk
Item-grupper: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00655252

dbGaP phs000942 Use of WGS for Diagnosis and Discovery in the Cancer Genetics Clinic - Eligibility

- 2024-11-27 - 5 Formulär, 1 Item-grupp, 1 Dataelement, 1 Språk
Item-grupp: IG.elig
Principal Investigator: Theodora S. Ross, MD, PhD, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA, and Department of Cancer Genetics, UT Southwestern Medical Center, Dallas, TX, USA MeSH: Neoplasms,Breast Neoplasms,Ovarian Neoplasms,Peritoneal Neoplasms,Skin Neoplasms,Esophageal Neoplasms,Thyroid Neoplasms,Urinary Bladder Neoplasms,Endometrial Neoplasms,Fallopian Tube Neoplasms,Melanoma,Testicular Neoplasms,Bile Duct Neoplasms,Lung Neoplasms,Colonic Neoplasms,Adrenocortical Carcinoma,Carcinoma, Renal Cell,Colonic Polyps,Adenomatous Polyposis Coli,Lymphoma, Large B-Cell, Diffuse,Pheochromocytoma,Paraganglioma,Leiomyoma,Hemangioblastoma,Hyperparathyroidism,Pancreatic Neoplasms,Vulvar Neoplasms,Brain Neoplasms,Liver Neoplasms,Kidney Neoplasms,Prostatic Neoplasms,Glioblastoma,Oncocytoma, renal https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000942 Despite the potential of whole-genome sequencing (WGS) to improve patient diagnosis and care, the empirical value of WGS in the cancer genetics clinic is unknown. We performed WGS on members of two cohorts of cancer genetics patients: those with BRCA1/2 mutations (n = 176) and those without (n = 82). Initial analysis of potentially pathogenic variants (PPVs, defined as nonsynonymous variants with allele frequency 1% in ESP6500) in 163 clinically-relevant genes suggested that WGS will provide useful clinical results. This is despite the fact that a majority of PPVs were novel missense variants likely to be classified as variants of unknown significance (VUS). Furthermore, previously reported pathogenic missense variants did not always associate with their predicted diseases in our patients. This suggests that the clinical use of WGS will require large-scale efforts to consolidate WGS and patient data to improve accuracy of interpretation of rare variants. While loss-of-function (LoF) variants represented only a small fraction of PPVs, WGS identified additional cancer risk LoF PPVs in patients with known BRCA1/2 mutations and led to cancer risk diagnoses in 21% of non-BRCA cancer genetics patients after expanding our analysis to 3209 ClinVar genes. These data illustrate how WGS can be used to improve our ability to discover patients' cancer genetic risks. "Reprinted from doi:10.1016/j.ebiom.2014.12.003, with permission from EBioMedicine."

pht004834.v1.p1

1 Item-grupp 5 Dataelement

pht004835.v1.p1

1 Item-grupp 5 Dataelement

pht004836.v1.p1

1 Item-grupp 16 Dataelement

pht004837.v1.p1

1 Item-grupp 5 Dataelement

Kidney Cancer NCT00378703 Eligibility - E2804 Registration Worsksheet - 2680170v1.0 - E2804 Registration Worsksheet

- 2021-09-17 - 1 Formulär, 3 Item-grupper, 27 Dataelement, 1 Språk
Item-grupper: Eligibility, Demographic Data Required For Patient Registration, I have reviewed the above data and agree the date are accurate and correct
E2804 Registration Worsksheet Bevacizumab, Sorafenib, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=39DE83BC-8CC5-21F3-E044-0003BA3F9857

Kidney Cancer NCT00326898 Treatment - E2805 Concomitant Medication Form - 2444090v1.0 - E2805 Concomitant Medication Form

- 2017-07-14 - 1 Formulär, 3 Item-grupper, 34 Dataelement, 1 Språk
Item-grupper: Administrative documentation, Concomitant medication, Comments
E2805 Concomitant Medication Form Sunitinib or Sorafenib in Treating Patients With Kidney Cancer That Was Removed By Surgery Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=0B593E1B-ACB3-37BB-E044-0003BA3F9857

Kidney Cancer NCT01198158 On-Study - CALGB 90802 On-Study Form - 3107346v1.0 - CALGB 90802 On-Study Form

- 2015-01-09 - 1 Formulär, 7 Item-grupper, 57 Dataelement, 1 Språk
Item-grupper: Header Module, PATIENT DESCRIPTION, SITES OF DISEASE, BASELINE LABORATORY DATA, Urinalysis, PRIOR TREATMENT, Footer Module
CALGB 90802 On-Study Form Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=88715713-3A23-2D6C-E040-BB89AD433D3B

dbGaP phs001271 Pooled Genome-Wide Analysis of Kidney Cancer Risk (KIDRISK) - pht006116.v1.p1

- 2023-03-20 - 5 Formulär, 1 Item-grupp, 4 Dataelement, 1 Språk
Item-grupp: pht006116
Principal Investigator: Ghislaine Scélo, PhD, International Agency for Research on Cancer (IARC), Lyon, France MeSH: Carcinoma, Renal Cell,Kidney Neoplasms https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001271 Incidence rates of renal cell carcinoma (RCC) are rising and the latest estimates show that it accounts for over 300,000 cases and 120,000 deaths worldwide each year. Mechanisms underlying RCC occurrence are not fully understood and a large part of the disease heritability remains unexplained. The study aimed at augmenting the size of available RCC genome-wide association studies to increase the statistical power to detect genetic variants associated with the disease. The study includes genome-wide genotyping data from RCC cases (n=2,781) and controls (n=2,526) recruited in Western Europe, Central and Eastern Europe, and Australia.

pht006117.v1.p1

1 Item-grupp 3 Dataelement

pht006118.v1.p1

1 Item-grupp 4 Dataelement

pht006119.v1.p1

1 Item-grupp 6 Dataelement

Eligibility

1 Item-grupp 1 Dataelement

Kidney Cancer NCT01198158 Registration - CALGB 90802 Registration Worksheet Form - 3103555v1.0 - CALGB 90802 Registration Worksheet Form

- 2021-09-20 - 1 Formulär, 10 Item-grupper, 44 Dataelement, 1 Språk
Item-grupper: Header Module, Protocol Administration, Patient Demographics/Pre-Treatment Characteristics1, Patient Demographics/Pre-Treatment Characteristics2, Patient Demographics/Pre-Treatment Characteristics3, Certification Of Eligibility, Protocol Design, Initial Patient Consent For Specimen Use, CALGB 580902, Registration Information
CALGB 90802 Registration Worksheet Form Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=879626AD-DB8C-4AF2-E040-BB89AD4364E1

Kidney Cancer NCT00357760 Eligibility - E4805 Registration Worsksheet - Step 1 - 3056754v1.0 - E4805 Registration Worsksheet - Step 1

- 2021-09-20 - 1 Formulär, 3 Item-grupper, 26 Dataelement, 1 Språk
Item-grupper: Eligibility, Demographic Data Required For Patient Registration, I have reviewed the above data and agree the date are accurate and correct
E4805 Registration Worsksheet - Step 1 VEGF Trap in Treating Patients With Metastatic or Unresectable Kidney Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=83D1F61D-EFC6-FE74-E040-BB89AD436539

Kontakt

Använd detta formulär för feedback, frågor och förslag på förbättringar.

Fält markerade med * är obligatoriska.

Hjälp

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial